Commercial, Academic Collaboration Leads to Discovery of Bone Mass Gene

"Drink milk," advertisements demand. Fight osteoporosis before bone loss occurs. They make a good point, considering that nothing on the market will restore a significant amount of lost bone mass. Current therapies can only stop or help slow down the process. However, scientists at Chiroscience Research and Development in Bothell, Wash., hope to actually treat osteoporosis. They have identified a novel gene coding for a protein that may be involved in bone-density control. This "bone mass gene

Written byNadia Halim
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

"Drink milk," advertisements demand. Fight osteoporosis before bone loss occurs. They make a good point, considering that nothing on the market will restore a significant amount of lost bone mass. Current therapies can only stop or help slow down the process. However, scientists at Chiroscience Research and Development in Bothell, Wash., hope to actually treat osteoporosis.

They have identified a novel gene coding for a protein that may be involved in bone-density control. This "bone mass gene" is altered in all patients suffering from a rare bone growth disorder known as sclerosteosis. The condition is found in the Afrikaner (South African of Dutch descent) population and causes bones to gain mass throughout the affected person's life, the opposite of osteoporosis. Cells called osteoclasts dissolve worn-out bone while other cells called osteoblasts generate new bone. As people age, bone removal exceeds bone formation. When this happens too quickly or when people ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies